Product #: K002

CH50 Assay

The CH50 assay is a functional test of the classical complement pathway in serum or plasma.

CH50 test kit (100 determinations)

Price (EU): €565 (valid from 01-01-2026)
Customers outside the European Union: please request a quotation.


Order test kit
CH50 test kit
Description

Haemolytic complement assays are functional tests of the classical and alternative complement pathways in serum or plasma. The classical pathway assay (CH50) is based on the lysis of antibody-sensitized sheep erythrocytes in the presence of Ca2+ and Mg2+. It is useful as a screening test when complement deficiency or consumption is suspected. The assay is sensitive to the reduction, absence and/or inactivity of any component of the pathway.

This method is also suited to assess the effects of pharmaceuticals on inhibition or consumption of complement components. The assay can also be used to evaluate the haemocompatibility of biomaterials and medical devices in accordance with ISO 10993-4:2017, by measuring complement activity in blood, plasma or serum after contact with the material. Activation of the complement system by biomaterials or pharmaceuticals can result in consumption of complement proteins, which reduces the CH50 level.

Application

Measuring classical pathway complement activity. Plasma or serum samples from the following species can be analysed: human, guinea pig, hamster, rat, rabbit, cow (bovine), pig (swine), rhesus macaque and dog (beagle). This kit is intended for laboratory research use only and is not for use in diagnostic or therapeutic procedures. The analysis should be performed by trained laboratory professionals.

Principle

An erythrocyte suspension is incubated with serially diluted serum or plasma for 30 minutes at 37 °C. Complement activation results in lysis of the erythrocytes. After incubation the samples are centrifuged to obtain supernatant. The free haemoglobin concentration in the supernatant, which reflects the degree of complement-mediated lysis, is measured by means of a spectrophotometer at a wavelength of 415 nm. The CH50 is calculated by plotting the degree of haemolysis against the percentage of plasma; in our method it is defined as the percentage of plasma that produces 50% lysis.

The positive reference is total lysis induced by lysis fluid and the negative reference is obtained after incubation with dilution buffer.

The kit requires only a small sample volume (25 µL) and is performed in a 96-well round-bottom microplate or in microcentrifuge tubes.

Video protocol for the CH50 Assay kit.
Storage and Stability

Product is stable at 4 °C for at least six weeks.

Download

Manual / SDS

Publications using the CH50 kit:
  1. Wu WK, Ukita R, Patel YJ, Cortelli M, Trinh VQ, Ziogas IA, Francois SA, Mentz M, Cardwell NL, Talackine JR, Grogan WM, Stokes JW, Lee YA, Kim J, Alexopoulos SP, Bacchetta M. Xenogeneic cross-circulation for physiological support and recovery of ex vivo human livers. Hepatology. 2023 Sep 1;78(3):820-834.

  2. Sülzen H, Began J, Dhillon A, Kereïche S, Pompach P, Votrubova J, Zahedifard F, Šubrtova A, Šafner M, Hubalek M, Thompson M, Zoltner M, Zoll S. Cryo-EM structures of Trypanosoma brucei gambiense ISG65 with human complement C3 and C3b and their roles in alternative pathway restriction. Nat Commun. 2023 Apr 27;14(1):2403.

  3. Lang Balija M, Štimac A, Košutić Gulija T, Gudan Kurilj A, Bekavac A, Plećaš A, Halassy B, Jagušić M, Forčić D. Evaluation of the Interactions between Mumps Virus and Guinea Pig. J Virol. 2023 Apr 27;97(4):e0035923.

  4. Wu WK, Stier MT, Stokes JW, Ukita R, Patel YJ, Cortelli M, Landstreet SR, Talackine JR, Cardwell NL, Simonds EM, Mentz M, Lowe C, Benson C, Demarest CT, Alexopoulos SP, Shaver CM, Bacchetta M. Immune characterization of a xenogeneic human lung cross-circulation support system. Sci Adv. 2023 Mar 31;9(13):eade7647.

  5. Weisser NE, Sanches M, Escobar-Cabrera E, O’Toole J, Whalen E, Chan PWY, Wickman G, Abraham L, Choi K, Harbourne B, Samiotakis A, Rojas AH, Volkers G, Wong J, Atkinson CE, Baardsnes J, Worrall LJ, Browman D, Smith EE, Baichoo P, Cheng CW, Guedia J, Kang S, Mukhopadhyay A, Newhook L, Ohrn A, Raghunatha P, Zago-Schmitt M, Schrag JD, Smith J, Zwierzchowski P, Scurll JM, Fung V, Black S, Strynadka NCJ, Gold MR, Presta LG, Ng G, Dixit S. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat Commun. 2023 Mar 13;14(1):1394.

  6. Khosousi S, Hye A, Velayudhan L, Bloth B, Tsitsi P, Markaki I, Svenningsson P. Complement system changes in blood in Parkinson’s disease and progressive Supranuclear Palsy/Corticobasal Syndrome. Parkinsonism Relat Disord. 2023 Mar;108:105313.

  7. Quint WH, Matečko-Burmann I, Schilcher I, Löffler T, Schöll M, Burmann BM, Vogels T. Bispecific Tau Antibodies with Additional Binding to C1q or Alpha-Synuclein. J Alzheimers Dis. 2021;80(2):813-829.

  8. Pinnapireddy SR , Giselbrecht J , Strehlow B , Janich C , Husteden C , Meister A , Loppnow H , Sedding D , Erdmann F , Hause G , Brezesinski G , Groth T , Langner A , Bakowsky U , Wölk C . A triple chain polycationic peptide-mimicking amphiphile - efficient DNA-transfer without co-lipids. Biomater Sci. 2019 Dec 17;8(1):232-249.

  9. Giselbrecht J, Wiedemann S, Reddy Pinnapireddy S, Goergen N, Loppnow H, Sedding D, Erdmann F, Bakowsky U, Hause G, Lúcio M, Langner A, Wölk C. Nucleic acid carrier composed of a branched fatty acid lysine conjugate-Interaction studies with blood components. Colloids Surf B Biointerfaces. 2019 Dec 1;184:110547.

  10. Garaulet G, Lazcano JJ, Alarcón H, de Frutos S, Martínez-Torrecuadrada JL, Rodríguez A. Display of the Albumin-Binding Domain in the Envelope Improves Lentiviral Vector Bioavailability. Hum Gene Ther Methods. 2017 Dec;28(6):340-351.

  11. Akhouri RR, Goel S, Furusho H, Skoglund U, Wahlgren M. Architecture of Human IgM in Complex with P. falciparum Erythrocyte Membrane Protein 1. Cell Rep. 2016 Feb 2;14(4):723-736.

  12. Misra SK, Chang HH, Mukherjee P, Tiwari S, Ohoka A, Pan D. Regulating Biocompatibility of Carbon Spheres via Defined Nanoscale Chemistry and a Careful Selection of Surface Functionalities. Sci Rep. 2015 Oct 14;5:14986.

  13. Mukherjee P, Misra SK, Gryka MC, Chang HH, Tiwari S, Wilson WL, Scott JW, Bhargava R, Pan D. Tunable Luminescent Carbon Nanospheres with Well-Defined Nanoscale Chemistry for Synchronized Imaging and Therapy. Small. 2015 Sep;11(36):4691-703.

  14. Luo J, Lindstrom J. Antigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravis. J Immunol. 2014 Nov 15;193(10):5044-55.